SEC Comment Letter for Viking Therapeutics, Inc. (VKTX) (CIK 0001607678) (VKTX) — Aug 2, 2021
Viking Therapeutics, Inc. (VKTX) (CIK 0001607678)
Date: Aug. 2, 2021 · CIK: 0001607678 · Accession: 0000000000-21-009419
AI Filing Summary & Sentiment
File numbers found in text: 333-258231
Letter
United States securities and exchange commission logo August 2, 2021 Brian Lian, Ph.D. President and Chief Executive Officer Viking Therapeutics, Inc. 12340 El Camino Real, Suite 250 San Diego, CA 92130 Re:Viking Therapeutics, Inc. Registration Statement on Form S-3 Filed July 28, 2021 File No. 333-258231 Dear Dr. Lian: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Ansart at (202) 551-4511 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Samantha Eldredge
Show Raw Text
United States securities and exchange commission logo
August 2, 2021
Brian Lian, Ph.D.
President and Chief Executive Officer
Viking Therapeutics, Inc.
12340 El Camino Real, Suite 250
San Diego, CA 92130
Re:Viking Therapeutics, Inc.
Registration Statement on Form S-3
Filed July 28, 2021
File No. 333-258231
Dear Dr. Lian:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Ansart at (202) 551-4511 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Samantha Eldredge